Lynwood Capital Management Inc. Bellus Health Inc. Transaction History

Lynwood Capital Management Inc.

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Oct 25, 2022	SELL	$8.95 - $12.0 $127,188 - $170,532	-14,211 Reduced 36.24%	25,000 $264,000
Q2 2022 Aug 02, 2022	SELL	$6.46 - $10.02 $65,174 - $101,091	-10,089 Reduced 20.46%	39,211 $362,000
Q1 2022 May 05, 2022	BUY	$5.56 - $7.99 $274,108 - $393,907	49,300 New	49,300 $339,000

128K

Ticker BLU
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 125,793,000
Description
BELLUS Health Inc., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. Its lead product candidate includes BLU-5937, an antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of RCC and chronic pruritus. Th...

Get notified when there are updates to the investment portfolio of Lynwood Capital Management Inc., based on Form 13F filings with the SEC.

Stay updated on Lynwood Capital Management Inc. with notifications on news.